Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2020

01-12-2020 | Expectoration | Research article

Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations

Authors: Seyed Ahmad Tabatabaii, Ghamartaj Khanbabaee, Saeed Sadr, Nazanin Farahbakhsh, Maryam Kazemi Aghdam, Saran Lotfollahzadeh, Amirhossein Hosseini, Naghi Dara, Mohammad Nanbakhsh, Fatemeh Abdollah Gorji

Published in: BMC Pulmonary Medicine | Issue 1/2020

Login to get access

Abstract

Background

Early detection of pulmonary contamination in children with cystic fibrosis (CF) is essential since these children are vulnerable to Pseudomonas aeruginosa (P. aeruginosa) colonization. In Iran, home nebulization of antibiotics is a widespread practice in treatment for patients with CF and, to the best our knowledge, no bacteriological surveys have been conducted till date in this regard.

Method

This observational, cross sectional study was conducted on 61 children with CF at Mofid Children’s Hospital, Tehran, from September 2017 to march 2018. The swab sampling was performed from 61 home nebulizers used by children diagnosed with CF. Contemporaneous sputum sample or deep nasopharyngeal swab was taken from each patient for bacterial and fungal testing. Medical records of the patients were reviewed and the number of exacerbations were recorded over the last 12 months prior to the study enrollment.

Results

The results of study showed that, 43 (70.5%) nebulizers were contaminated; 31 (50.8%) mouthpieces, 21 (34.4%) reservoirs, and 11 (18%) connecting tubes. The most common organism to be isolated was P. aeruginosa and was recovered from 19 (31%) nebulizers, 16 of them belonged to patients chronically colonized with P. aeruginosa. The remaining three had at least one positive sputum culture for P. aeruginosa in the past 1 year before the study. There was a significant increase in the number of CF exacerbations with an average number of exacerbation being 1.5 ± 1(SD) over last 12 months in children who had pathogenic organisms recovered from their home nebulizers compared with 0.4 ± 0.7(SD) exacerbations per year in whom non-pathogenic organisms were isolated from their nebulizers (P < 0.001).

Conclusion

The majority of domiciliary nebulizers used by children with CF were contaminated with microorganisms indicating that the nebulizers may serve as potential reservoirs of pathogens for the patients’ lung. Perpetuating colonization is a possible concern in the ones recently colonized with P. aeruginosa and, therefore, decontamination of nebulizer requires more attention to prevent ongoing infection. The negative impact of contamination of nebulizer on CF exacerbation requires serious attention and further investigations.
Literature
1.
2.
go back to reference Farjadian S, Moghtaderi M, Kashef S, Alyasin S, Najib K, Saki F. Clinical and genetic features in patients with cystic fibrosis in southwestern Iran. Iran J Pediatr. 2013;23(2):212–5.PubMedPubMedCentral Farjadian S, Moghtaderi M, Kashef S, Alyasin S, Najib K, Saki F. Clinical and genetic features in patients with cystic fibrosis in southwestern Iran. Iran J Pediatr. 2013;23(2):212–5.PubMedPubMedCentral
3.
go back to reference Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–51.CrossRef Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–51.CrossRef
4.
go back to reference VanDevanter DR, Kahle JS, O'Sullivan AK, Sikirica S, Hodgkins PS. Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment. J Cyst Fibros. 2016;15(2):147–57.CrossRef VanDevanter DR, Kahle JS, O'Sullivan AK, Sikirica S, Hodgkins PS. Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment. J Cyst Fibros. 2016;15(2):147–57.CrossRef
5.
go back to reference Fajac I, Wainwright CE. New treatments targeting the basic defects in cystic fibrosis. Presse Med. 2017;46(6 Pt 2):e165–e75.CrossRef Fajac I, Wainwright CE. New treatments targeting the basic defects in cystic fibrosis. Presse Med. 2017;46(6 Pt 2):e165–e75.CrossRef
6.
go back to reference Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros. 2010;9(1):1–16.CrossRef Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros. 2010;9(1):1–16.CrossRef
7.
go back to reference Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157–70.CrossRef Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157–70.CrossRef
8.
go back to reference Arias Llorente RP, Bousono Garcia C, Diaz Martin JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros. 2008;7(5):359–67.CrossRef Arias Llorente RP, Bousono Garcia C, Diaz Martin JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros. 2008;7(5):359–67.CrossRef
9.
go back to reference Gaspar MC, Couet W, Olivier JC, Pais AA, Sousa JJ. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis. 2013;32(10):1231–52.CrossRef Gaspar MC, Couet W, Olivier JC, Pais AA, Sousa JJ. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis. 2013;32(10):1231–52.CrossRef
10.
go back to reference Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16(1):174.CrossRef Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16(1):174.CrossRef
11.
go back to reference Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol. 1996;34(3):584–7.CrossRef Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol. 1996;34(3):584–7.CrossRef
12.
go back to reference Cohen HA, Kahan E, Cohen Z, Sarrell M, Beni S, Grosman Z, et al. Microbial colonization of nebulizers used by asthmatic children. Pediatr Int. 2006;48(5):454–8.CrossRef Cohen HA, Kahan E, Cohen Z, Sarrell M, Beni S, Grosman Z, et al. Microbial colonization of nebulizers used by asthmatic children. Pediatr Int. 2006;48(5):454–8.CrossRef
13.
go back to reference Blau H, Mussaffi H, Mei Zahav M, Prais D, Livne M, Czitron BM, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007;33(4):491–5.CrossRef Blau H, Mussaffi H, Mei Zahav M, Prais D, Livne M, Czitron BM, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007;33(4):491–5.CrossRef
14.
go back to reference Carvalho TC, Peters JI, Williams RO 3rd. Influence of particle size on regional lung deposition--what evidence is there? Int J Pharm. 2011;406(1–2):1–10.CrossRef Carvalho TC, Peters JI, Williams RO 3rd. Influence of particle size on regional lung deposition--what evidence is there? Int J Pharm. 2011;406(1–2):1–10.CrossRef
15.
go back to reference Brzezinski LX, Riedi CA, Kussek P, Souza HH, Rosario N. Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients? J Bras Pneumol. 2011;37(3):341–7.CrossRef Brzezinski LX, Riedi CA, Kussek P, Souza HH, Rosario N. Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients? J Bras Pneumol. 2011;37(3):341–7.CrossRef
16.
go back to reference Della Zuana A, Garcia Dde O, Juliani RC, Silva Filho LV. Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers. J Bras Pneumol. 2014;40(2):119–27.CrossRef Della Zuana A, Garcia Dde O, Juliani RC, Silva Filho LV. Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers. J Bras Pneumol. 2014;40(2):119–27.CrossRef
17.
go back to reference Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003;24(5 Suppl):S6–52.CrossRef Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003;24(5 Suppl):S6–52.CrossRef
18.
go back to reference Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Seventh Informational Supplement. CLSI Document M100-S27. Wayne, PA: Clinical and Laboratory Standards Institute; 2017. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Seventh Informational Supplement. CLSI Document M100-S27. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
19.
go back to reference Pitchford KC, Corey M, Highsmith AK, Perlman R, Bannatyne R, Gold R, et al. Pseudomonas species contamination of cystic fibrosis patients’ home inhalation equipment. J Pediatr. 1987;111(2):212–6.CrossRef Pitchford KC, Corey M, Highsmith AK, Perlman R, Bannatyne R, Gold R, et al. Pseudomonas species contamination of cystic fibrosis patients’ home inhalation equipment. J Pediatr. 1987;111(2):212–6.CrossRef
20.
go back to reference Vassal S, Taamma R, Marty N, Sardet A. d'athis P, Bremont F, et al. microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control. 2000;28(5):347–51.CrossRef Vassal S, Taamma R, Marty N, Sardet A. d'athis P, Bremont F, et al. microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control. 2000;28(5):347–51.CrossRef
21.
go back to reference Khanbabaee G, Akbarizadeh M, Sayyari A, Ashayeri-Panah M, Abdollahgorji F, Sheibani K, et al. A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. Braz J Infect Dis. 2012;16(2):122–8.PubMed Khanbabaee G, Akbarizadeh M, Sayyari A, Ashayeri-Panah M, Abdollahgorji F, Sheibani K, et al. A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. Braz J Infect Dis. 2012;16(2):122–8.PubMed
22.
go back to reference Rosenfeld M, Joy P, Nguyen CD, Krzewinski J, Burns JL. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough? J Hosp Infect. 2001;49(3):229–30.CrossRef Rosenfeld M, Joy P, Nguyen CD, Krzewinski J, Burns JL. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough? J Hosp Infect. 2001;49(3):229–30.CrossRef
23.
go back to reference Waters V, Ratjen F. Pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. 2015;12(Suppl 2):S200–6.PubMed Waters V, Ratjen F. Pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. 2015;12(Suppl 2):S200–6.PubMed
24.
go back to reference Hoppe JE, Wagner BD, Sagel SD, Accurso FJ, Zemanick ET. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulm Med. 2017;17(1):188.CrossRef Hoppe JE, Wagner BD, Sagel SD, Accurso FJ, Zemanick ET. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulm Med. 2017;17(1):188.CrossRef
Metadata
Title
Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations
Authors
Seyed Ahmad Tabatabaii
Ghamartaj Khanbabaee
Saeed Sadr
Nazanin Farahbakhsh
Maryam Kazemi Aghdam
Saran Lotfollahzadeh
Amirhossein Hosseini
Naghi Dara
Mohammad Nanbakhsh
Fatemeh Abdollah Gorji
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-1059-4

Other articles of this Issue 1/2020

BMC Pulmonary Medicine 1/2020 Go to the issue